TG Therapeutics TGTX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's EPS (basic)?
- TG Therapeutics (TGTX) reported EPS (basic) of $0.14 in Q1 2026.
- How has TG Therapeutics's EPS (basic) changed year-over-year?
- TG Therapeutics's EPS (basic) increased by 366.7% year-over-year, from $0.03 to $0.14.
- What is the long-term trend for TG Therapeutics's EPS (basic)?
- Over 3 years (2021 to 2025), TG Therapeutics's EPS (basic) has grown at a 5.7% compound annual growth rate (CAGR), from -$2.63 to $3.11.
- What does EPS (basic) mean?
- The amount of profit attributed to each share of common stock.
- How do you interpret EPS (basic)?
- An increasing trend indicates that the company is generating more profit per share, which is generally positive for stock valuation.
- How does EPS (basic) compare across companies?
- Standardized metric used by investors to compare per-share earnings across the market.